Log in with your email address username.


[Comment] Vilanterol fluticasone and mortality in comorbid COPD GOLD B

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Due to common risk factors such as smoking and ageing, COPD often coexists with cardiovascular diseases, which have a major effect on prognosis. Cardiovascular death is the most important cause of death in patients with symptomatic moderate COPD (ie, COPD GOLD B).1,2 However, as highlighted by the GOLD guidelines, none of the current treatments of COPD, except smoking cessation, has been shown to significantly decrease all-cause mortality.